RapTr Cell Line Development Services Introduced
June 20, 2017
San Diego, CA — June 20, 2017 — Aragen Bioscience, Inc, a leading pre-clinical contract research organization specializing in the discovery and preclinical development of high-value biotech and pharmaceutical products, announced today at the BIO International Convention the introduction of RapTr™ services. RapTr™ Cell Line Development Services combine the proven CHO-DG44 host cell line and vector combination with an innovative clone selection process. The results are a highly flexible and customizable platform delivering high titers in a rapid timeframe from early stage Discovery through to the Clinic. RapTr also incorporates state-of-the-art analytical methods to characterize and evaluate product quality at all stages. As RapTr is based on CHO-DG44, it is regulatory-friendly and royalty-free.
“Building on our decades of experience in cell line development and recent investments in expanding our biologics team and facilities, we’re excited to announce RapTr™. We believe that our suite protein expression and analytical services will give our clients tremendous flexibility in developing cell lines and generating high quality proteins using a single scalable platform regardless of their stage of development.” said Oren Beske, Ph.D., President of Aragen Bioscience.
About Aragen Bioscience, Inc.
Aragen Bioscience, Inc., a wholly-owned subsidiary of GVK BIO, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of In Vitro and In Vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products.